Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/9042
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOsei, Silas Acheampong-
dc.contributor.authorBiney, Robert Peter-
dc.contributor.authorObese, Ernest-
dc.contributor.authorAgbenyeku, Mary Atta-Panyi-
dc.contributor.authorAttah, Isaac Yaw-
dc.contributor.authorAmeyaw, Elvis Ofori-
dc.contributor.authorBoampong, Johnson Nyarko-
dc.date.accessioned2023-10-05T09:45:26Z-
dc.date.available2023-10-05T09:45:26Z-
dc.date.issued2021-02-
dc.identifier.urihttp://hdl.handle.net/123456789/9042-
dc.description.abstractBackground: Evidence of plasmodium resistance to some of the current antimalarial agents makes it imperative to search for newer and effective drugs to combat malaria. Therefore, this study evaluated whether the co-administrations of xylopic acid-amodiaquine and xylopic acid- artesunate combinations will produce synergistic antimalarial effect. Methods: Antiplasmodial effect of xylopic acid (XA: 3, 10, 30, 100, 150 mg kg-1), artesunate (ART: 1, 2, 4, 8, 16 mg kg-1), and amodiaquine (AQ: 1.25, 2.5, 5, 10, 20 mg kg-1) were evaluated in Plasmodium berghei ANKA-infected mice to determine respective ED50s. Artemether/lumefantrine (AL: 1.14/6.9) p.o. was used as the positive control. XA/ART and XA/AQ were subsequently administered in a fixed-dose combination of their ED50s (1:1) and the combination fractions of their ED50s (1/2, 1/4, 1/8, 1/16, and 1/32) to determine the experimental ED50s (Zexp). An isobologram was constructed to determine the nature of the interaction between XA/ART, and XA/AQ combinations by comparing Zexp with the theoretical ED50 (Zadd). Body weight and 30-day survival post-treatment were additionally recorded. Results: ED50s for XA, ART, and AQ were 9.0 ± 3.2, 1.61 ± 0.6, and 3.1 ± 0.8 mg kg-1 respectively. The Zadd, Zexp and interaction index for XA/ART co-administration was 5.3 ± 2.61, 1.98 ± 0.25 and 0.37, respectively while that of XA/AQ were 6.05 ± 2.0, 1.69 ± 0.42, and 0.28 respectively. The Zexp for both combination therapies lay significantly (p<0.001) below the additive isoboles showing XA acts synergistically with both ART and AQ in clearing the parasites. High doses of XA/ART combination significantly (p<0.05) increased the survival days of infected mice with a mean hazard ratio of 0.40 while all the XA/AQ combination doses showed a significant (p<0.05) increase in the survival days of infected mice with a mean hazard ratio of 0.27 similar to AL. Both XA/ART and XA/AQ combined treatments significantly (p<0.05) reduced weight loss. Conclusion: Xylopic acid co-administration with either artesunate or amodiaquine produces a synergistic anti-plasmodial effect in mice infected with Plasmodium berghei ANKA.en_US
dc.language.isoenen_US
dc.publisherPubMeden_US
dc.subjectAntimalarial drugsen_US
dc.subjectCombination therapiesen_US
dc.subjectIsobolographic analysisen_US
dc.subjectXylopic aciden_US
dc.subjectArtesunateen_US
dc.subjectAmodiaquineen_US
dc.subjectsynergismen_US
dc.subjectPlamsodium berghei.en_US
dc.titleXylopic Acid-Amodiaquine and Xylopic Acid-Artesunate Combinations are Effective in Managing Malaria in Plasmodium Berghei-infected Mice.en_US
dc.typeArticleen_US
Appears in Collections:School of Allied Health Sciences



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.